News stories about aTyr Pharma (NASDAQ:LIFE) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. aTyr Pharma earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.7453329158592 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

LIFE has been the subject of several recent research reports. Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Wednesday, July 12th. ValuEngine lowered aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the company a “hold” rating in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies started coverage on aTyr Pharma in a report on Thursday, September 7th. They set an “overweight” rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. aTyr Pharma has an average rating of “Hold” and a consensus target price of $4.27.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.06.

In related news, Director Paul Schimmel acquired 94,336 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were purchased at an average price of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now directly owns 40,440 shares of the company’s stock, valued at $107,166. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Mendlein acquired 37,736 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, for a total transaction of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “aTyr Pharma (LIFE) Given Media Impact Rating of 0.13” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with's FREE daily email newsletter.